Scholar Rock Price Target Raised to $65 Following FDA Approval of ISEMBYLD

Key Facts

1Jefferies raised the price target for Scholar Rock to $65 following the FDA approval of its spinal muscular atrophy drug, ISEMBYLD.

2The company set the list price for the new drug ISEMBYLD at $11,659 per single-use vial.

3The FDA granted Scholar Rock a Rare Pediatric Disease Priority Review Voucher in recognition of the approval.

Following weeks of anticipation in the biotech sector, Scholar Rock received U.S. FDA approval for ISEMBYLD, the first muscle-targeted therapy designed to improve motor function in spinal muscular atrophy (SMA) patients. In response to this milestone, Jefferies analyst Amy Li raised the price target for the stock from $57 to $65, citing the drug's significant commercial potential. Additionally, the FDA granted the company a Rare Pediatric Disease Priority Review Voucher in recognition of this achievement.

The company has established a list price of $11,659 per single-use vial for ISEMBYLD, a move expected to bolster its fundamental valuation. Per market data, Scholar Rock's market capitalization stands at approximately $6.21 billion, as the approval marks a strategic pivot for the firm in treating severe neuromuscular disorders.

As of the close on September 14, 2026, SRRK shares stood at $51.85, having reached an intraday high of $56.90. Investors are now focused on the commercial rollout of the new therapy and its impact on future earnings, while the upcoming economic calendar shows no immediate sector-specific catalysts for the pharmaceutical industry in the next few days.